Clovis Oncology Inc (CLVS), Sarepta Therapeutics Inc (SRPT): Three Healthcare Stocks to Keep an Eye On

Another one to watch

The main reason for possible FDA acceleration is that Eteplirsen is the the only drug that has proven to increase the level of dystrophin: the protein whose deficiency is currently considered the main cause for the muscular dystrophy.

With that said, investor interest is likely to spike in the back half of this year when the Phase III trials of the drug begin and the FDA makes a decision on the outlook of the drug. Definitely keep an eye out for Sarepta Therapeutics Inc (NASDAQ:SRPT) in the coming months.

Even when the rest of the country struggled with the recession just a few years ago, the health care industry grew over 50%. Healthcare is still growing faster than the rest of the economy and National Health Expenditures (NHE) as a share of GDP is expected to reach 19.6% by 2019. The above mentioned stocks show signs of potential near-term growth, and investors should definitely keep an eye on them.

Chris Johnson has no position in any stocks mentioned. The Motley Fool has no position in any of the stocks mentioned. Chris is a member of The Motley Fool Blog Network — entries represent the personal opinion of the blogger and are not formally edited.

The article 3 Healthcare Stocks to Keep an Eye On originally appeared on Fool.com is written by Chris Johnson.

Copyright © 1995 – 2013 The Motley Fool, LLC. All rights reserved. The Motley Fool has a disclosure policy.